Clinical and Biological Prognostic Factors in Follicular Lymphoma
- PMID: 32586571
- DOI: 10.1016/j.hoc.2020.02.002
Clinical and Biological Prognostic Factors in Follicular Lymphoma
Abstract
Follicular lymphoma comprises approximately 20-30% of all cases of B-cell lymphomas. Median survival has improved significantly in the modern era. Prognostic factors include histologic grade, cytogenetics, molecular mutations, the tumor microenvironment, and tumor burden. Clinical prognostic indices are available and increasingly incorporate genetic information. Prognostic factors also arise during the course of treatment. Early progression within 24 months of initial chemoimmunotherapy is an adverse prognostic marker of inferior survival. Other high-risk populations include those with double refractory disease or those with high risk of transformation to diffuse large B-cell lymphoma.
Keywords: Biological risk factors; Clinical risk factors; Follicular lymphoma; Prognostic indices.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure A.A. Patel: no disclosures. S.M. Smith: Consulting for TG Therapeutics, Bayer, Genentech, Celgene in past 12 months.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
